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A novel immobilization strategy for electrochemical 
detection of cancer biomarkers: DNA-directed 
immobilization of aptamer sensors for sensitive 
detection of prostate specific antigen†   
Zhugen Yanga,b*, Barbara Kasprzyk-Horderna, Sean Gogginsa ,Christopher G. Frosta*, 
Pedro Estrelab 
We report on a novel strategy for DNA aptamer 
immobilization to develop sensitive electrochemical detection 
of protein biomarker, with prostate specific antigen (PSA) as 
a case biomarker. Thiolated single-stranded DNA (ssDNA) 
was co-immobilized with 3-mercapto-1-propannol on gold 
electrodes, and used as a scaffold for DNA aptamer 
attachment through hybridization of the aptamer overhang 
(so-called “DNA-directed immobilization aptamer sensors”, 
DDIAS). In the approach, the complementary DNA aptamer 
against PSA was assembled by the probe ssDNA onto the 
electrode to detect PSA; or the probe ssDNA directly 
hybridized with complementary DNA aptamer/PSA complex 
following their pre-incubation in solution, so-called ‘on-chip’ 
and ‘in-solution’ method, respectively. A double stranded 
DNA intercalator with ferrocenyl (Fc) redox marker was 
synthesized to evaluate the feasibility of the strategy. Results 
demonstrate that ‘in-solution’ method offers a favourable 
media (in homogenous solution) for the binding between the 
aptamer and PSA, which shows to be more efficient than ‘on-
chip’ approach. DDIAS show promising analytical 
performance under optimized conditions, with a limit of 
detection in the range of fM and low non-specific adsorption. 
 
Cancer is a leading cause of death and accounted for 8.2 million 
deaths in 2012 worldwide according to the report of World Health 
Organization (WHO), and prostate cancer is the fifth cause of 
cancer-related deaths. However, the chance of treating cancer could 
be increased if it could be diagnosed at an early stage. Prostate 
specific antigen (PSA) is a biomarker that has played a significant 
role for the detection of prostate cancer, in particular in clinical 
serum samples1, 2. A PSA level of 4 ng/mL in human serum sample 
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is usually regarded as the cut-off value for potential diagnosis as 
prostate cancer 3. To this end, it is essential to develop ultra-sensitive 
and specific biosensors for accurate PSA detection for early cancer 
diagnosis. Even though PSA is currently not considered as a very 
reliable biomarker, there is general consensus that future diagnostic 
devices will need to test for a panel of biomarkers, which includes 
PSA.      
      DNA aptamers have proven to be powerful tools in the fields of 
molecular recognition and biosensors due to their low cost, ease of 
synthesis and application as electrochemical biosensors because of 
bearing negative charge 4-7. Compared to antibodies, aptamers are 
stable and able to sustain reversible denaturation 7. A DNA aptamer 
against PSA was identified by Savory and co-workers in 20108, and 
several groups have been using it for PSA sensing9-11. Signal 
amplification with nanoparticles is found to improve the limit of 
detection (LOD) of PSA9, 11. However, the complicated 
immobilization procedures and facile aggregation of the 
nanoparticles were observed to limit the utility of this sensor 
platform.  
DNA-directed immobilization (DDI) was firstly proposed by 
Wacker et al 12, 13 for multiplexed antigen detection, based on the 
self-assembly of semi-synthetic DNA-protein conjugates to generate 
a protein microarray assay. In this strategy, protein tumour marker 
carcinoembryonic antigen (CEA) was employed as a model system 
and the detection limit could reach as low as pg/mL range. Chevolot 
and co-workers14-16 further developed the DDI method for a 
glycoarray, which used glycoconjugate molecules that present a 
DNA sequence for anchoring onto DNA chips through 
hybridization. The in-solution approach was performed by allowing 
saccharide/lectin recognition before immobilization by hybridization 
on the surfaces and subsequent detection. The developed glycoarray 
using DDI method showed promising analytical performance with 
detection limit at nM range. However, DDI for both protein 
microarray and glycoarray required the challenging semi-synthesis 
of DNA anchoring antibody or carbohydrate and troublesome 
purification steps.   
Here, we propose to use a DDI strategy for aptamer 
immobilization: DNA-directed immobilization of aptamer sensors 
(DDIAS), which does not require the synthesis of DNA-protein or 
DNA-carbohydrate complexes. We introduced the aptamer, which 
serves as the function of protein modified single-stranded DNA 
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(ssDNA), as the specific linker to assemble the antigen onto the 
electrode. A ssDNA probe was firstly co-immobilized with 3-
mercapto-1-propanol (MCP) onto the electrode as a scaffold. The 
surface density can be effectively controlled to allow efficient 
hybridization with complementary DNA aptamer 17. The 
complementary DNA aptamer against PSA could be assembled on 
the electrode to bind with PSA; or the probe ssDNA directly 
hybridized with complementary DNA aptamer/PSA complex 
following their pre-incubation in solution, so-called ‘on-chip’ and 
‘in-solution’ method, respectively (Scheme 1). In particular, the ‘in-
solution’ method allows the aptamer and PSA binding in a 
homogenous media, which was expected to be more sensitive for 
PSA detection. To limit the competition binding with ssDNA probe 
from “free aptamer” (<10 kDa) and aptamer/PSA complex (>33 
kDa) , a filtration device was employed to separate them according 
to their different molecule weight, which further implement the 
previous DDI approach13, 14, 16. This protocol simplified the 
elaboration of the biosensor and can be used as a general effective 
immobilization strategy for the detection of versatile analytes. 
Additionally, compared to typical direct immobilization of aptamer 
onto a solid substrate, the linear linkage of DNA will allow sufficient 
steric space for the active site of aptamer to bind with the protein and 
prevent the formation of secondary structure of the DNA aptamer. 
To the best of our knowledge, this is the first time this method with 
aptamer sensors has been demonstrated to detect cancer biomarker.  
 
  
Scheme.1. Illustration of the strategy for the elaboration of DNA-directed 
immobilization aptamer sensors (DDIAS) for PSA detection: (a) ‘on-chip’ 
method and (b) ‘in-solution’ method, aptamer and PSA were incubated in 
solution and then the unbinding aptamer was removed with a filtration 
device.  
 
Fig. 1A presents a typical Nyquist plot of the DDIAS for the 
detection of PSA at 10 µg/mL with ‘on-chip’ and ‘in-solution’ 
method. Note that even though the electrodes for ‘on-chip’ and ‘in-
solution’ method are different, the initial resistance of the 
ssDNA/MCP layer on the electrodes is reproducible following the 
same cleaning and immobilization procedures. Keighley et al. 17 
optimized the surface density of ssDNA by co-immobilization of 6-
mercapto-1-hexanol (MCH) to get a highly efficient hybridization 
with complementary strand DNA using a label-free EIS assay. The 
maximum percentage change of charge transfer resistance upon 
hybridization with fully complementary target oligonucleotides was 
obtained from oligonucleotide probes electrodes co-immobilized 
with MCH at a DNA mole fraction of 20%. The electrodes in our 
experiment were designed with the ratio between probe ssDNA and 
MCP at 1:3 (ssDNA mole fraction at 25%) for high hybridization 
efficiency. The change of charge transfer resistance (ΔRct) to the 
background of ssDNA was proportional to each binding event, such 
as hybridization of complementary aptamer, detection of PSA using 
‘on-chip’ and ‘in-solution’ method. Fig.1 A shows that both DNA 
hybridization and PSA binding increased the charge transfer 
resistance, and ΔRct shifted by 12.5% for the hybridization of 
complementary aptamer with probe ssDNA. The detection of PSA 
either with ‘in-solution’ or ‘on-chip’ method lead to a significant 
change of ΔRct, 27.6 % and 98.6 %, respectively. As shown in Fig.1 
B, electrodes functionalized with ssDNA probe were employed to 
incubate with PSA as control, and only a small shift of charge 
transfer resistance (2.1 %) was observed, indicating that ssDNA 
cannot specifically bind PSA and co-immobilization of ssDNA/MCP 
could play a useful role of limiting the non-specific adsorption of 
PSA on the electrode surface.  
    In the EIS measurement, negatively charged ferri/ferrocyanide 
couple [Fe(CN)6]3-/4- was employed as the redox marker for 
electrochemical characterization, thus the diffusion of [Fe(CN)6]3-/4- 
and mass loading of PSA onto the surface of the electrodes have a 
significant effect on the charge transfer resistance. The electrodes 
modified with ssDNA are negatively charged, and as more negative 
charges were introduced onto the surface upon hybridization with 
aptamer, the redox maker diffusion to the surface of the electrodes is 
hindered due to repulsive interactions. Thus, charge transfer 
resistance shifts to a high value upon the aptamer hybridization with 
ssDNA probe are observed. These results are in agreement with our 
early report using EIS for DNA detection17, 18. 
Fig.1. (A) Typical Nyquist plot of DDIAS for PSA detection, electrodes was 
functionalized with ssDNA probe, aptamer hybridized with ssDNA probe, 
PSA binding with aptamer with ‘on-chip’ and in-solution method, 
respectively; (B) change of charge transfer resistance (ΔRct) of the different 
layers on electrodes surface interpreted from Fig.1 A; (C) Differential pulse 
voltammetry (DPV) measurement of electrodes modified with ssDNA 
aptamer, ssDNA probe binding with aptamer and ssDNA probe binding with 
aptamer/PSA complex incubation with FND intercalator, and the ssDNA 
aptamer without incubation with FND was recorded as blank. The data was 
recorded from at least 3 individual electrodes. 
 
Additionally, the binding with PSA leads to an increase of charge 
transfer resistance due to a high mass loading on the surface of the 
electrodes, which will hinder the redox maker approaching the 
surface. Interestingly, the ‘in-solution’ method for PSA detection 
induced a significant shift of charge transfer resistance compared to 
the ‘on-chip’ method, indicating that the ‘in-solution’ approach is 
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more efficient than ‘on-chip’ for PSA detection. This was associated 
with the fact that the ‘in-solution’ method offers a homogeneous 
binding media for aptamer and PSA; however, the aptamer binding 
with PSA takes place in a solid-liquid phase for the ‘on-chip’ 
method. Upon the binding event between ssDNA probe and 
aptamer/PSA, the increase in mass loading as well as negative 
charge of the aptamer account for the increase in charge transfer 
resistance. For the ‘on-chip’ method, the aptamer was firstly 
assembled by hybridization on the electrodes, leading to steric 
hindrance for PSA to attach onto the electrode surface. 
Consequently, the ‘in-solution’ method is promising and effective 
for PSA detection, and it will be further optimized for highly 
sensitive detection.  
To evaluate the hybridization of the ssDNA probe with DNA 
aptamer/PSA complex, a ferrocene intercalators (N,N’-((((((1,3,6,8-
tetraoxo-1,3,6,8-tetrahydrobenzo [lmn] [3,8] phenanthroline-2,7-
diyl) bis(ethane-2,1-diyl)) bis(oxy)) bis(ethane-2,1-diyl))bis(oxy)) 
bis (ethane-2,1-diyl)) diferrocenamide, FND) was synthesized 
(Scheme S1) to bind with dsDNA from aptamer/PSA complex with 
ssDNA probe. The synthesis protocols are presented in the 
supporting information. Fig.1 C illustrates the interaction between 
intercalator and ssDNA aptamer, dsDNA and the dsDNA/PSA 
complex characterized with Differential pulse voltammetry (DPV) 
measurement without redox markers in the electrolyte. The current 
depends on the interaction between intercalator and biomolecules 
functionalized on the electrodes. As shown in Fig. 1 C, a small 
current can be measured from ssDNA aptamer and FND. FND is a 
double stranded DNA intercalator which can bind with the duplex 
helix structure, and is not able to specifically bind with ssDNA19. 
However, the secondary conformation of the anti-PSA aptamer 
(internal duplex due to the loop structure formed) may be formed 
after the immobilization on the electrodes 8. The small current 
observed from ssDNA is likely due to the binding between the 
intercalator and the aptamer structure. DNA hybridization increases 
the current due to more double stranded DNA formed on the 
electrodes, indicating that ssDNA probe as a scaffold could well 
direct the assembly of aptamer/PSA complex onto the electrodes. 
The measured current of dsDNA from hybridization of probe ssDNA 
with aptamer ssDNA was higher than that from hybridization with 
aptamer ssDNA/PSA complex. This was associated with less duplex 
helix structures being generated for aptamer/PSA hybridization due 
to the steric hindrance of PSA on the electrodes. In conclusion, the 
DPV results offer evidence that the DNA hybridization could direct 
the assembly of the aptamer/PSA complex formed in solution onto 
the electrodes.   
The change in charge transfer resistance of the electrodes before 
and after binding with intercalators was recorded and the results 
show that the intercalator increases the charge transfer resistance 
(see Fig. S1). Therefore, the synthesized intercalator could 
potentially be employed for signal enhancement for our DDIAS. 
This could be comparable with our recently reported cobalt complex 
for enhancing impedimetric DNA detection 20. For our DDIAS 
platform, the enhanced charge transfer resistance was achieved after 
incubation with ferrocence intercalators. As the intercalators are 
neutral, the impedimetric signal enhancement is likely due to the 
expansion of the dsDNA and stronger charge barriers on electrodes 
after incubation with intercalators, leading to the difficulty of 
ferri/ferrocyanide redox marker to diffuse onto the surface of 
electrodes. Furthermore, it is possible that the introduction of 
ferrocene intercalators may help drive the generation of the loop 
structure of the aptamer, which leads to an increase in the change 
transfer resistance of the system. A systematic study of the binding 
between ferrocenyl intercalators and full complementary dsDNA is 
currently under investigation. 
      In order to improve the analytical performance of the developed 
aptamer sensors for the ultrasensitive detection of the real samples, 
the surface density of immobilized ssDNA probe and the 
concentration of aptamer were optimized. Various concentrations of 
aptamer (from 5 µM to 5 nM) were investigated by firstly binding 
with 50 ng/mL PSA (1.5 nM) in solution, and then the aptamer/PSA 
complexes were filtrated and hybridized with ssDNA probe on the 
electrode. As shown in Fig. 2A, the highest ΔRct value was obtained 
at 50 nM of aptamer and it shifted to lower values with increasing 
aptamer concentration. At higher aptamer concentration ranges 
(from 50 nM to 5 µM), the quantity of aptamer molecules was 
excessive to that of PSA in solution as the aptamer and PSA were 
incubated with the equivalent volume. Even though the aptamer/PSA 
complex was filtrated, it’s likely to remain tiny amount of excessive 
“free aptamers”. When the solution was transferred onto electrodes, 
there may be a competitive binding with ssDNA probe between the 
excessive aptamer and aptamer/PSA complexes. The same portion of 
aptamre/PSA complex binding on electrodes, compared to the 
aptamer, will lead to increased shifts of charge transfer resistance 
due to the additional high mass load of PSA onto the surface of 
electrodes meantime. However, the lower concentration of aptamer 
at 5 nM probably obtain less portion of aptamer/PSA complex in 
solution, which make the ΔRct shift to lower value. An equilibrium 
may exist on the binding between aptamer and PSA, the lower 
concentration of aptamer reduced the yields of aptamer/PSA 
complexes. As a result, the aptamer concentration was optimized at 
50 nM affording the highest ΔRct, which allows the sensitive 
detection of PSA using the ‘in-solution’ method.  
Fig.2. Optimization of ‘in-solution’ method for PSA detection (A) Effects of 
aptamer concentration on ΔRct and (B) effect of the molar ratio between 
probe ssDNA and MCP on ΔRct of aptamer sensors. 
    The molar ratio between probe ssDNA and MCP on electrodes is 
crucial for the DDIAS, as it determines the surface density and 
hybridization with complementary aptamer or aptamer/PSA 
complex. More importantly, MCP plays a role in limiting non-
specific adsorption, which is particularly essential to be optimized 
for protein detection. Fig. 2B shows the effect of various mole ratios 
between ssDNA probe and MCP on the ΔRct value. The optimal 
value for the detection of 50 ng/mL PSA was obtained for a 1:10 
ratio, which allows a low surface density on the electrodes and keeps 
high DNA hybridization efficiency. Compared to the optimal ratio 
(ssDNA: MCH, 1:4) for DNA assay in our early report 17, the 
fraction of MCP increased in our PSA assay under the optimized 
condition. The relatively lower density of DNA probe will be easier 
attached by the aptamer/PSA complex; furthermore, the higher MCP 
ratio would be more efficient for limiting non-specific adsorption of 
PSA.  
    As a result, the surface density and the aptamer concentration 
were optimized to obtain a high variation on the charge transfer 
resistance values. The optimized DDIAS is shown to be a promising 
tool for the detection of PSA, and in particular the ‘in-solution’ 
method can be potentially used for the detection of other 
biomolecules as the binding event takes place in solution. Under the 
optimized conditions, we employed DDIAS to detect various 
concentrations of PSA to evaluate the analytical performance of the 
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sensors. As shown in Fig. 3A, ΔRct increased with increasing PSA 
concentration, and the detection of 0.5 pg/mL (1.5 fM) of PSA could 
be reached with a ΔRct value of 12.1%. This value is higher than the 
one (ΔRct 8.2%) obtained for control experiments with 10 µg/mL 
BSA as a reference protein for non-specific adsorption. The LOD 
was estimated to around 0.5 pg/mL (1.5 fM) (3σ) in solution, and a 
dynamic range was obtained from 0.05 ng/mL to 50 ng/mL 
(R2=0.985). Chen et al. 10 proposed detection PSA using resonance 
light scattering (RLS) spectral assay based on PSA aptamer modified 
gold nanoparticles (AuNPs) and could sensitively detect 0.032 
ng/mL PSA. Liu et al. 9 developed an aptamer sensing platform of a 
graphite electrode modified with gold nanoparticles covered with 
graphitized mesoporous carbon nanoparticles for human PSA 
detection, based on the signal amplification of the biotin-avidin 
system. They were able to quantitatively measure PSA concentration 
range from 0.25 to 200 ng/mL, with a lowest LOD of 0.25 ng/mL. 
An optimized enzyme-linked immunosorbent assay (ELISA), which 
is the gold standard and most widely used assay for PSA, was 
reported to obtain a LOD at ng/mL range10. Compared to these 
reports, our DDIAS could reach a LOD at pg/mL range without any 
signal amplification procedures. Fig. 3B presents the non-specific 
adsorption evaluation of the developed DDIAS by interaction with 
10 µg/mL BSA and PSA, respectively. For the developed DDIAS, 
there are changes of charge transfer resistance for BSA detection 
from both ‘on-chip’ and ‘in-solution’ method. For the ‘on-chip’ 
method, ΔRct was 7.5 % and 27.6 % for BSA and PSA detection, 
respectively. However, the ‘in-solution’ method is demonstrated to 
be more effective in obtaining positive signal (ΔRct from PSA at 98.6 
%, BSA at 8.2%) from detection of the same concentration of PSA 
and BSA. It is suggested that the ‘in-solution’ method is more 
specific and favourable for PSA detection, which could be 
potentially employed for the detection of proteins in complex 
samples. Moreover, in order to investigate the stability of the 
customized biosensors, the measurements were performed before 
and after the incubation of electrodes with 5 M sodium chloride 
(NaCl) solution, and the results (Fig. S2) show that the signal has no 
changes from incubation with NaCl. This indicates that our DDIAS 
is able to withstand salt solution, which will be beneficial for the 
detection of PSA in complex media.   
Fig.3. (A) Effects of different concentration of PSA on the ΔRct performed ‘in-
solution’ method (B) comparison of non-specific adsorption of DDIAS 
between ‘on-chip’ and ‘in-solution’ method with BSA as control. 
    In summary, we have demonstrated a novel strategy for aptamer 
immobilization with DNA-directed immobilization method for 
cancer biomarker detection with electrochemical impedance 
spectroscopy. The ‘in-solution’ and ‘on-chip’ methods were 
compared, and we conclude that the ‘in-solution’ approach is more 
effective due to the homogenous binding media for aptamer and 
protein. The feasibility was validated with double stranded DNA 
intercalators synthesized in-house. We demonstrated that the DDIAS 
is able to sensitively detect PSA at the fM range under optimized 
parameters, and favourable for limiting non-specific adsorption. 
Additionally, the proposed strategy could be further used for a wide 
range of protein cancer biomarkers detection, such as peptide, 
protein or even small molecules like drugs assuming that a specific 
DNA aptamer candidate is available. We hope to use the effective 
DDIAS for the detection of the cancer biomarker in real samples, 
such as serum, urine as well as wastewater for epidemiological 
studies. The versatile and sensitive biosensors will be beneficial for 
the application in the fields of healthcare and environmental 
monitoring.  
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